# Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

> **NCT00005039** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 86 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **BIOLOGICAL:** recombinant fowlpox-prostate specific antigen vaccine
- **BIOLOGICAL:** recombinant vaccinia prostate-specific antigen vaccine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00005039
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-01
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005039, "Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00005039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*